Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine open-label extension in moderate to severe Alzheimer's disease
NCT00857233Phase 3Terminated
- Sponsor
- Lundbeck
- Start
- Jun 2004
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of memantine in Alzheimer's disease (AD), sponsored by Lundbeck. Primary endpoints: Number of Patients With Adverse Events (AEs) at 24 weeks and Percentage of Patients Who Withdrew Due to Intolerance to Treatment at 24 weeks. Started Jun 2004; status: terminated.
02
Drugs
memantine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00857233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00857233.